Here, the clinical, histopathological, and molecular pathological characteristics, targeted therapy, and prognosis of two patients with NSCLC exhibiting coexistence of NTRK2 fusion and EGFR mutations are presented to enhance understanding of such rare gene covariations and provide a basis for precise targeted therapy in NSCLC. The gene discussed is NTRK2; the disease is non-small cell lung carcinoma.